Rituximab therapy for Type I membranoproliferative glomerulonephritis.

Abstract

Rituximab reduced proteinuria among patients with Type I MPGN. This trial suggests that B cells may play a role in this disease and that additional study of B-cell suppression is warranted.

Full Text

EBSCO - full-text online
Dustri-Verlag Dr. Karl Feistle GmbH & Co. KG - full-text online

Subjects

Similar articles

Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies. (2010-07-19)
A Single Dose of Rituximab Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and Function. (2013-04-09)
Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. (2009-12-07)
Bendamustine in chronic lymphocytic leukemia and refractory lymphoma. (2008-09-01)
Reactivation of latent viruses in individuals receiving rituximab for new onset type 1 diabetes. (2013-02-17)
The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma. (2006-07-18)
Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. (2009-02-17)
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. (2008-11-07)
Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions. (2009-11-05)

Authors

Publication date

2012-03-26

Journal

Clinical nephrology
Clin Nephrol (0301-0430)

Journal topics

Language

Eng.

Copyright

Clinical nephrology

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. dillon.john [at] mayo.edu

Release reference

Clin Nephrol. 2012 Apr;77(4):290-5

Related books

Español | English

© Galenicom 1999-2013